Skip to main content
. 2019 Jul 2;10(8):1187–1192. doi: 10.1021/acsmedchemlett.9b00221

Figure 1.

Figure 1

Compounds used for the present study. Compounds 1–3 are patented immunomodulators from Aurigene, hypothesized to disrupt the PD-1/PD-L1 interaction. Compound 4 is a known inhibitor developed by Bristol-Myers Squibb, employed here as a positive control.